, - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • adamwangwang47 adamwangwang47 Apr 30, 2013 4:14 PM Flag

    Lomitapide inhibits the microsomal triglyceride transfer protein (MTP or MTTP) which is necessary for very low-density lipoprotein (VLDL) as

    fatty liver will show up after taking for 12-18 months

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • system_architect_enterprise system_architect_enterprise Apr 30, 2013 4:26 PM Flag

      Of course, if they don't take the drug, they will be dead, so I guess I'd take the drug and then deal with a fatty liver.

      • 1 Reply to system_architect_enterprise
      • you don't know what you are talking about:

        Heterozygous FH is a common genetic disorder, inherited in an autosomal dominant pattern, occurring in 1:500 people in most countries; Heterozygous FH is normally treated with statins, bile acid sequestrants or other hypolipidemic agents that lower cholesterol levels.

        Homozygous FH is much rarer, occurring in 1 in a million births.

        How many patients are there in the US?

        according to new release 8/9/12, ...Aegerion hasn’t revealed its pricing plan for lomitapide, but Beer says he expects it will fall in the range of $200,000 to $400,000 per patient per year. The consensus among the analysts covering the company is that Aegerion will bring in $26.5 million in sales next year (2013)...

        drug itself is dirty cheap to make...patients outside of US will not be paying anything close to $200,000 per patient per year (maybe $2000 in India/China and other countries the drug prices are much lower or out of IP protected areas; plus through oversea mailing order)

        Good luck

        Sentiment: Strong Sell

20.19-14.02(-40.98%)Oct 31 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.